U.S. Markets closed

Acorda Therapeutics enrolls first patient for rHIgM22 clinical trial

Mayo Clinic and Acorda Therapeutics announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis. This is a Phase 1 clinical trial enrolling people with MS to assess the safety and tolerability of rHIgM22. The study also includes several exploratory efficacy measures.